Reflections: Food Seasoned with Love  |  Guest Column: The Psychotherapist with Fur and Four Legs!  |  Health Monitor: Dealing With Post Covid Syndrome  |  National Edu News: Secretary Higher Education urges students to emerge as job creators  |  National Edu News: PM addresses the 18th Convocation of Tezpur University, Assam  |  Leadership Instincts: Experts highlight the need for strengthening centre-state cooperation  |  Policy Indications: India’s global position rises both in innovations & publications  |  Education Information: Written Result of Indian Economic Service/Indian Statistical Service Examination  |  National Edu News: AstroSat’s Ultraviolet Imaging Telescope spots rare ultraviolet-bright stars  |  Parent Interventions: Randomized trials could help to return children safely to schools   |  Parent Interventions: How fellow students improve your own grades   |  Parent Interventions: School-made lunch 'better' for children  |  Teacher Insights: Second Anniversary of India Science, Nation’s OTT Channel  |  Leadership Instincts: Participation of MGIEP in the Implementation of NEP 2020  |  Teacher Insights: World of Puzzling Patterns  |  
April 12, 2020 Sunday 09:43:50 PM IST

Isolating genes encoding antibodies for neutralising the SARS-CoV-2, COVID-19

Science Innovations

Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for treatment of numerous disease conditions such as Diphtheria, Tetanus, Rabies, and  Ebola. Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2. In India, one such effort is being led by Professor Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology, Government of India.  

Professor Chaudhary’s group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection. These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes. This work is being undertaken as part of an Anti-COVID consortium under the leadership of Prof. Chaudhary and involving Dr. Amulya Panda at the National Institute of Immunology and Dr. Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).


Comments